Latest Breaking News On - Foundation research center - Page 3 : comparemela.com

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The Company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth US$111.2 Billion by 2027, according to current analysis by Emergen Research.

Spain generalAitor gonzJames nathanielszJulian kenyonProfit research organizationUniversity of granadaCompany registration statement on formCompany mechanism of actionExchange commissionEmergen researchFoundation research centerPropanc biopharma incPropanc biopharmaProenzymes optimization projectResearch centerNon profit research organization